Loading...
XHKG
8622
Market cap25mUSD
Dec 05, Last price  
0.40HKD
1D
-21.00%
1Q
0.00%
IPO
-7.06%
Name

Huakang Biomedical Holdings Co Ltd

Chart & Performance

D1W1MN
XHKG:8622 chart
P/E
P/S
7.08
EPS
Div Yield, %
Shrs. gr., 5y
3.82%
Rev. gr., 5y
-0.09%
Revenues
25m
+2.96%
19,456,00025,410,00026,541,00028,677,00025,471,00021,967,00026,127,00025,330,00024,629,00025,359,000
Net income
-4m
L-28.09%
7,934,0008,426,000-1,952,000-459,000-284,000-11,627,000-4,220,000-3,075,000-5,782,000-4,158,000
CFO
-3m
L+6,277.08%
5,455,00011,255,0002,699,000951,000-3,390,000-3,924,000-2,378,0001,286,000-48,000-3,061,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.
IPO date
Dec 13, 2018
Employees
80
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT